- Home
- YQ vs IBIO Comparison
YQ vs IBIO Comparison
Compare YQ & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- IBIO
- Stock Information
- Founded
- YQ 2012
- IBIO 2008
- Country
- YQ China
- IBIO United States
- Employees
- YQ N/A
- IBIO N/A
- Industry
- YQ Other Consumer Services
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- IBIO Health Care
- Exchange
- YQ Nasdaq
- IBIO Nasdaq
- Market Cap
- YQ 19.4M
- IBIO 15.9M
- IPO Year
- YQ 2020
- IBIO N/A
- Fundamental
- Price
- YQ $2.23
- IBIO $0.81
- Analyst Decision
- YQ
- IBIO Strong Buy
- Analyst Count
- YQ 0
- IBIO 3
- Target Price
- YQ N/A
- IBIO $4.87
- AVG Volume (30 Days)
- YQ 56.7K
- IBIO 5.4M
- Earning Date
- YQ 09-03-2025
- IBIO 05-02-2025
- Dividend Yield
- YQ N/A
- IBIO N/A
- EPS Growth
- YQ N/A
- IBIO N/A
- EPS
- YQ N/A
- IBIO N/A
- Revenue
- YQ $25,546,613.00
- IBIO $375,000.00
- Revenue This Year
- YQ N/A
- IBIO $36.00
- Revenue Next Year
- YQ N/A
- IBIO N/A
- P/E Ratio
- YQ N/A
- IBIO N/A
- Revenue Growth
- YQ N/A
- IBIO 650.00
- 52 Week Low
- YQ $1.26
- IBIO $0.64
- 52 Week High
- YQ $3.19
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- YQ 57.45
- IBIO 47.34
- Support Level
- YQ $2.15
- IBIO $0.71
- Resistance Level
- YQ $2.39
- IBIO $0.87
- Average True Range (ATR)
- YQ 0.16
- IBIO 0.08
- MACD
- YQ 0.00
- IBIO 0.02
- Stochastic Oscillator
- YQ 54.29
- IBIO 37.39
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.